BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 17717428)

  • 1. Does polysomy of chromosome 17 have a role in ERBB2 and topoisomerase IIalpha expression? Gene, mRNA and protein expression: a comprehensive analysis.
    Corzo C; Bellosillo B; Corominas JM; Salido M; Coll MD; Serrano S; Albanell J; Solé F; Tusquets I
    Tumour Biol; 2007; 28(4):221-8. PubMed ID: 17717428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. c-erbB2 and topoisomerase IIalpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study.
    Fritz P; Cabrera CM; Dippon J; Gerteis A; Simon W; Aulitzky WE; van der Kuip H
    Breast Cancer Res; 2005; 7(3):R374-84. PubMed ID: 15987433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
    Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
    Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlations of TOP2A gene aberrations and expression of topoisomerase IIα protein and TOP2A mRNA expression in primary breast cancer: a retrospective study of 86 cases using fluorescence in situ hybridization and immunohistochemistry.
    Meng H; Chen R; Li W; Xu L; Xu L
    Pathol Int; 2012 Jun; 62(6):391-9. PubMed ID: 22612507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer.
    Coon JS; Marcus E; Gupta-Burt S; Seelig S; Jacobson K; Chen S; Renta V; Fronda G; Preisler HD
    Clin Cancer Res; 2002 Apr; 8(4):1061-7. PubMed ID: 11948114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
    Salido M; Tusquets I; Corominas JM; Suarez M; Espinet B; Corzo C; Bellet M; Fabregat X; Serrano S; Solé F
    Breast Cancer Res; 2005; 7(2):R267-73. PubMed ID: 15743507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.
    Järvinen TA; Tanner M; Rantanen V; Bärlund M; Borg A; Grénman S; Isola J
    Am J Pathol; 2000 Mar; 156(3):839-47. PubMed ID: 10702400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
    Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer.
    Schindlbeck C; Mayr D; Olivier C; Rack B; Engelstaedter V; Jueckstock J; Jenderek C; Andergassen U; Jeschke U; Friese K
    J Cancer Res Clin Oncol; 2010 Jul; 136(7):1029-37. PubMed ID: 20052594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Her-2/neu and topoisomerase IIα in advanced breast cancer: a comprehensive FISH analysis of 245 cases.
    Engelstaedter V; Schiffers J; Kahlert S; Mainka P; Engel J; Kirchner T; Diebold J; Mayr D
    Diagn Mol Pathol; 2012 Jun; 21(2):77-83. PubMed ID: 22555090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
    Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
    Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Classical lobular breast carcinoma consistently lacks topoisomerase-IIα gene amplification: implications for the tailored use of anthracycline-based chemotherapies.
    Brunello E; Brunelli M; Manfrin E; Nottegar A; Bersani S; Vergine M; Molino A; Fiorio E; Chilosi M; Gobbo S; Martignoni G; Bonetti F
    Histopathology; 2012 Feb; 60(3):482-8. PubMed ID: 22168383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative quantification of ERBB2 mRNA in invasive duct carcinoma of the breast: correlation with ERBB-2 protein expression and ERBB2 gene copy number.
    Mrhalová M; Kodet R; Kalinová M; Hilská I
    Pathol Res Pract; 2003; 199(7):453-61. PubMed ID: 14521261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer.
    Järvinen TA; Kononen J; Pelto-Huikko M; Isola J
    Am J Pathol; 1996 Jun; 148(6):2073-82. PubMed ID: 8669491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene copy mapping of the ERBB2/TOP2A region in breast cancer.
    Jacobson KK; Morrison LE; Henderson BT; Blondin BA; Wilber KA; Legator MS; O'Hare A; Van Stedum SC; Proffitt JH; Seelig SA; Coon JS
    Genes Chromosomes Cancer; 2004 May; 40(1):19-31. PubMed ID: 15034864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of topoisomerase-IIalpha gene status between primary breast cancer and corresponding distant metastatic sites.
    Durbecq V; Di Leo A; Cardoso F; Rouas G; Leroy JY; Piccart M; Larsimont D
    Breast Cancer Res Treat; 2003 Feb; 77(3):199-204. PubMed ID: 12602919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer.
    Järvinen TA; Tanner M; Bärlund M; Borg A; Isola J
    Genes Chromosomes Cancer; 1999 Oct; 26(2):142-50. PubMed ID: 10469452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of topoisomerase 2A expression and gene change in operable invasive breast cancer.
    Qiao JH; Jiao DC; Lu ZD; Yang S; Liu ZZ
    Tumour Biol; 2015 Sep; 36(9):6833-8. PubMed ID: 25846735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer.
    Tanner M; Järvinen P; Isola J
    Cancer Res; 2001 Jul; 61(14):5345-8. PubMed ID: 11454672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased topoisomerase IIα expression and altered histone and regulatory factors of topoisomerase IIα promoter in patients with chronic benzene poisoning.
    Yu K; Shi YF; Yang KY; Zhuang Y; Zhu RH; Xu X; Cai G
    Toxicol Lett; 2011 Jun; 203(2):111-7. PubMed ID: 21382456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.